Previous 10 | Next 10 |
Kamada Limited (KMDA) Q2 2021 Earnings Conference Call August 11, 2021 08:30 ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Anthony Petrone - Jefferies Presentation Operator Greetin...
Second Quarter 2021 Revenues were $24.2 Million In Connection with the Transition of GLASSIA ® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an Approximately 10% Annual Labor Cost Reduction Pivotal...
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on W...
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children - Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in Childr...
Kamada Ltd. (KMDA) Q1 2021 Earnings Conference Call May 12, 2021 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Anthony Petrone – Jefferies Keay ...
Kamada (KMDA): Q1 GAAP EPS of $0.06 misses by $0.07.Revenue of $24.9M (-25.2% Y/Y) misses by $2.69M.Press Release For further details see: Kamada EPS misses by $0.07, misses on revenue
First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 Million In Connection with the Transition of GLASSIA® Manufacturing, the Product’s U.S. Biologics License Application will be Transferred to Takeda by the End of 2021 and Kamad...
REHOVOT, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2021, prior to the open of the U.S. financial markets on Wednesda...
Kamada ([[KMDA]] -0.3%) has announced an amendment to its license agreement with Takeda ([[TAK]] -3.0%) for Glassia, an intravenous FDA-approved therapy developed by the company for Alpha-1 Antitrypsin deficiency.The supplier of Glassia for Japanese pharma giant for distribution in ...
Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021 Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer Fi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...